Uploaded byEBAI
Mooren’s Ulcer
Mooren's ulcer is a painful and aggressive form of peripheral ulcerative keratitis requiring multimodal management. The document details its demographics, etiopathogenesis, clinical features, and treatment strategies, emphasizing the importance of immunosuppression and a step ladder approach for therapy. Successful outcomes often necessitate both medical and surgical interventions tailored to disease severity.
More Related Content
Similar to Mooren’s Ulcer
Mooren’s Ulcer
- 1. Mooren’s Ulcer The StepLadder Approach Jatin Ashar Mumbai Eye Care, Cornea and LASIK Centre
- 2. Layout Introduction Demographics Etiopathogenesis Clinical features Mimics Management Speical situations-cataractsurgery and pediatric patients
- 3. Introduction Peripheral ulcerative keratitiswith no scleral involvement ‘Ulcus Rodens’ Brown and McKenzie Painful, relentless, aggressive course Steep overhanging central edge Strats peripherally and eventually spreads circumferentially and centripetally
- 4. Demographics STUDY Arvind Study1 ChinaStudy2 L V P E I Study3 Subjects 242 eyes of 166 patients 715 eyes of 550 patients 244 eyes of 145 patients M:F 137:29 318:232 125:20 Age 13-95 yrs 14-79 yrs 10-74 yrs Risk factors Prior surgery, trauma Trauma, prior surgery Trauma Laterality Bilateral patients older than unilateral Bilateral patients older and more severe 1. Srinivas M, et al. BJO 2007 2. Chen N, et al. BJO 2000 3. Mathur A, Ashar J, Sangwan V (Unpublished data)
- 5. Etiopathogenesis Still elusive Autoimmune theory-cellmediated and humoral Histopathological evidence of plasma cell infiltration in superficial stroma, hyperactivity of fibroblasts in mid stroma, macrophage infiltration in deep stroma
- 6.
- 7.
- 8. signs Peripheral patchy infiltrates Epithelialdefect Shallow furrow Limbal invovlement Steep overhaning edge Circumferential spread and centripetal spread
- 10. Investigations Clinical features Rule ofinfectious process Systemic collagen vascular diseases-CBC, ESR, RA, ANA, VDRL, ANCA, XRAY Chest Systemic evaluation by physician
- 11. Mimics Infectious keratitis Marginal keratitis Rheumatoidarthritis Wegener’s granulomatosis Terrien’s degeneration
- 12.
- 13. Medical Management Topical steroids Systemicsteroids- oral Systemic steroids- intravenous pulse Methyl prednisolone Systemic immunomodulators- oral Methotrexate, Cyclophosphamide, Azathioprine Systemic immunomodulators- intravenous pulse cyclophosphamide
- 14. Topical Steroids Initial therapy Hourlyprednisolone acetate 1% Monitor epithelial healing Add prophylactic antibiotic
- 15. Systemic Immunosuppression Oral steroids-prednisolone 1mg/kg Cyclophosphamide 2mg/kg/day Methotrexate 7.5-12.5mg/week Azathioprine 2mg/kg/day Cyclosporine 10mg/kg/day
- 17. Step Ladder Approachfor Immunosuppression Step 1: Assess disease severity Step 2: Severity based therapy Step 3: Regular follow up and monitoring Step 4: Reassess and modify therapy when needed
- 18. Severity of Mooren’sulcer Number of clock hours Depth of stromal involvement • Clock hour based < 6 clock hours (2 quadrants) > 6 clock hours (2 quadrants) • Depth based <50% stromal loss >51-95% stromal loss >95% and perforation
- 20. Complications: • Most commoncomplication – infection • Recurrence of disease
- 21. Outcome of StepLadder Immunosuppression Approach Immunosuppression Number of cases receiving the therapy Success rate # Keratoplasty needed+ Topical steroids 145 Topical steroids alone 62 76% 3 Oral steroids 66 86% 12 Oral Methotrexate 14 78.5% 3 IVMP 7 71.4% 2 IVMP+IV cyclophosphamide 15 73.3% # Success defined as resolution of disease + Indicator of worsening of disease leading to perforation or severe thinning threatening the tectonic stability of cornea
- 22. Surgical Therapy Conjunctival resection-2clock hours either sides and 4mm posterior to limbus Superficial keratectomy Tissue adhesive Bandage contact lens
- 23. Surgical Therapy Amniotic membranetransplantation Patch graft Lamellar keratoplasty Penetrating keratoplasty Keratoprosthesis
- 24.
- 25. AMT for Mooren’sUlcer
- 26.
- 27. Outcomes of Patchgraft
- 28.
- 29.
- 30.
- 31.
- 32.
- 33. Special situations • Pediatricpopulation
- 34. Conclusion • Mooren’s ulceris often recalcitrant and aggressive disorder • A multimodality management is required to bring the disease under control • Immunosuppression is paramount to disease control • A systematic step ladder approach offers good results
- 35.